Cipolla S, Catapano P, Messina M, Pezzella P, Giordano G
Arch Womens Ment Health. 2023; 27(2):157-178.
PMID: 37957411
PMC: 10933171.
DOI: 10.1007/s00737-023-01394-1.
Deng Z, Robins P, Regenold W, Rohde P, Dannhauer M, Lisanby S
Neuropsychopharmacology. 2023; 49(1):150-162.
PMID: 37488281
PMC: 10700353.
DOI: 10.1038/s41386-023-01677-2.
Kim J, Kim T, Lee S, Koo J
Clin Psychopharmacol Neurosci. 2023; 21(3):429-446.
PMID: 37424412
PMC: 10335903.
DOI: 10.9758/cpn.22.1034.
Subramanian S, Labonte A, Nguyen T, Luong A, Hyche O, Smith S
Front Psychiatry. 2022; 13:996733.
PMID: 36405897
PMC: 9670172.
DOI: 10.3389/fpsyt.2022.996733.
Kittayarak K, Ittasakul P
Neuropsychiatr Dis Treat. 2022; 18:2477-2484.
PMID: 36338515
PMC: 9635544.
DOI: 10.2147/NDT.S385598.
Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions.
Miron J, Desbeaumes Jodoin V, Lesperance P, Blumberger D
Ther Adv Psychopharmacol. 2021; 11:20451253211042696.
PMID: 34589203
PMC: 8474312.
DOI: 10.1177/20451253211042696.
The Neurostimulation of the Brain in Depression Trial: Protocol for a Randomized Controlled Trial of Transcranial Direct Current Stimulation in Treatment-Resistant Depression.
Suleman R, Tucker B, Dursun S, Demas M
JMIR Res Protoc. 2021; 10(3):e22805.
PMID: 33729165
PMC: 8088846.
DOI: 10.2196/22805.
Unexpected cancellation on a catatonic patient's electroconvulsive therapy due to the coronavirus pandemic.
Casano K, Capone E
Gen Psychiatr. 2020; 33(6):e100271.
PMID: 33083693
PMC: 7520899.
DOI: 10.1136/gpsych-2020-100271.
Electroconvulsive Therapy and Schizophrenia: A Systematic Review.
Ali S, Mathur N, Malhotra A, Braga R
Mol Neuropsychiatry. 2019; 5(2):75-83.
PMID: 31192220
PMC: 6528094.
DOI: 10.1159/000497376.
Electroconvulsive therapy for treatment-resistant schizophrenia.
Sinclair D, Zhao S, Qi F, Nyakyoma K, Kwong J, Adams C
Cochrane Database Syst Rev. 2019; 3:CD011847.
PMID: 30888709
PMC: 6424225.
DOI: 10.1002/14651858.CD011847.pub2.
Junior medical students' knowledge about and attitudes towards electroconvulsive therapy in a South African setting.
Mausling M, Macharia M, Jordaan G
S Afr J Psychiatr. 2018; 23:1062.
PMID: 30263195
PMC: 6138198.
DOI: 10.4102/sajpsychiatry.v23i0.1062.
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.
Nucifora Jr F, Woznica E, Lee B, Cascella N, Sawa A
Neurobiol Dis. 2018; 131:104257.
PMID: 30170114
PMC: 6395548.
DOI: 10.1016/j.nbd.2018.08.016.
Toward an integrative perspective on the neural mechanisms underlying persistent maladaptive behaviors.
Diehl M, Lempert K, Parr A, Ballard I, Steele V, Smith D
Eur J Neurosci. 2018; 48(3):1870-1883.
PMID: 30044022
PMC: 6113118.
DOI: 10.1111/ejn.14083.
Thiopental is better than propofol for electroconvulsive therapy.
Nuzzi M, Delmonte D, Barbini B, Pasin L, Sottocorna O, Casiraghi G
Acta Biomed. 2018; 88(4):450-456.
PMID: 29350659
PMC: 6166177.
DOI: 10.23750/abm.v88i4.6094.
Impacts of Electroconvulsive Therapy on 1-Year Outcomes in Patients With Schizophrenia: A Controlled, Population-Based Mirror-Image Study.
Lin H, Liu S, Hsieh M, Chien Y, Chen I, Liao S
Schizophr Bull. 2017; 44(4):798-806.
PMID: 29036711
PMC: 6007329.
DOI: 10.1093/schbul/sbx136.
A Material History of Electroshock Therapy : Electroshock Technology in Europe until 1945.
Rzesnitzek L, Lang S
NTM. 2016; 24(3):251-277.
PMID: 27613376
DOI: 10.1007/s00048-016-0152-5.
Effects of ECT in treatment of depression: study protocol for a prospective neuroradiological study of acute and longitudinal effects on brain structure and function.
Oltedal L, Kessler U, Ersland L, Gruner R, Andreassen O, Haavik J
BMC Psychiatry. 2015; 15:94.
PMID: 25927716
PMC: 4422607.
DOI: 10.1186/s12888-015-0477-y.
Current electroconvulsive therapy practice and research in the geriatric population.
Kerner N, Prudic J
Neuropsychiatry (London). 2014; 4(1):33-54.
PMID: 24778709
PMC: 4000084.
DOI: 10.2217/npy.14.3.
Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review.
Andrade P, Noblesse L, Temel Y, Ackermans L, Lim L, Steinbusch H
Acta Neurochir (Wien). 2010; 152(4):565-77.
PMID: 20101419
PMC: 2844529.
DOI: 10.1007/s00701-009-0589-6.
A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.
Squires R, Saederup E
Neurochem Res. 1991; 16(10):1099-111.
PMID: 1686635
DOI: 10.1007/BF00966587.